Impact Bond: Development Impact Bond (DIB) for hepatitis C diagnosis and treatment financing - Cameroon
Stage of development: Complete
Policy sector: Health
Social challenge: High rates of undiagnosed and untreated chronic HCV infection, a treatable condition, in Cameroon
Primary SDG goal: 3
Date outcomes contract signed: 2019-12
Date contracts between all parties signed: 2020-01
Anticipated duration of service provision: 24
Total investment commitment currency: EUR
Total investment commitment: 230000
Total investment commitment (USD): 261364
Maximum potential outcome payment: 397800 EUR
Maximum potential outcome payment (USD): 452046
Target population: HCV-infected individuals (carriers)
Actual number of service users or beneficiaries engaged: 300
Actual unit type: Individual
Actual unit description: HCV-infected individuals (carriers)
Service and beneficiaries notes: The target was to identify around 500 antibody-HCV positive donors to enroll the planned 300 HCV- infected persons. Of the 500 antibody-HCV positive donors, it was assumed that 25% would have cleared the virus by themselves (i.e. antibody-HCV positive and HCV-RNA negative), 10% would be false positive (first anti-HCV testing in blood bank positive but not confirmed in second test) and about 10% will be lost to follow-up.
Changes to project due to COVID-19: Continue on outcomes contract with variations
Notes: The study was launched just before the COVID-19 pandemic and enrollment of patients was paused for six months. To continue the project, three agents – the investor, intermediary and outcome payer – agreed to invest additional money in the DIB. The total unexpected costs due to COVID-19 was €72,500 and was paid directly into the project as a once-off payment in January 2021.